Literature DB >> 15346583

Drug maker to pay $430 million in fines, civil damages.

.   

Abstract

Pharmaceutical manufacturer Warner-Lambert has agreed to plead guilty and pay more then $430 million to resolve criminal charges and civil liabilities in connection with its Parke-Davis division's illegal and fraudulent promotion of unapproved uses for the drug Neurontin (gabapentin). The drug was approved by the Food and Drug Administration in December 1993 solely for use with other drugs to control seizures in people with epilepsy.

Entities:  

Mesh：

Substances：

Year:  2004        PMID： 15346583

Source DB:  PubMed          Journal:  FDA Consum        ISSN： 0362-1332


  5 in total

1.  Preemption, tort reform, and pharmaceutical claims: Part two: Has the Food and Drug Administration shown it is solely responsible for the protection of patients? Can it do so? Will it do so?

Authors:  Russell G Thornton
Journal:  Proc (Bayl Univ Med Cent)       Date:  2008-01

2.  A protocol for a systematic review for perioperative pregabalin use.

Authors:  Naveen Eipe; John Penning; Mohammed Ansari; Fatemeh Yazdi; Nadera Ahmadzai
Journal:  Syst Rev       Date:  2012-09-13

3.  Biological rationale and potential clinical use of gabapentin and pregabalin in bipolar disorder, insomnia and anxiety: protocol for a systematic review and meta-analysis.

Authors:  Kerensa T Houghton; Alexandra Forrest; Amine Awad; Lauren Z Atkinson; Sarah Stockton; Paul J Harrison; John R Geddes; Andrea Cipriani
Journal:  BMJ Open       Date:  2017-03-27       Impact factor: 2.692

Review 4.  Gabapentin for Off-Label Use: Evidence-Based or Cause for Concern?

Authors:  Alyssa M Peckham; Kirk E Evoy; Leslie Ochs; Jordan R Covvey
Journal:  Subst Abuse       Date:  2018-09-23

5.  Pharmacotherapy of schizophrenic patients: preponderance of off-label drug use.

Authors:  David Pickar; Jessie Vinik; John J Bartko
Journal:  PLoS One       Date:  2008-09-10       Impact factor: 3.240
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.